What is NEUP's P/E ratio?

NEUPHORIA THERAPEUTICS INC (NEUP) currently trades at a P/E ratio of 9.10.

NEUPHORIA THERAPEUTICS INC reports a Return on Equity (ROE) of -93.64%.

What is NEUP's dividend yield?

NEUPHORIA THERAPEUTICS INC offers a dividend yield of 0.00%.

What is NEUP's Deepscope Quality Score?

Deepscope rates NEUP's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy NEUP?

Deepscope's AI Timing Score for NEUP is 56 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does NEUP belong to?

NEUPHORIA THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.

NEUP (NASDAQ) 株価分析 | NEUPHORIA THERAPEUTICS INC

Stock Check Daily update data at 9:30 AM
(Price: 2026-06-05 | FS: 2026-03-31)

NEUP

NEUPHORIA THERAPEUTICS INC

US:NASDAQ STOCK Healthcare >> Biotechnology News 75

USD 4.49

-0.35 (-7.23%) Day Change

Watchlist Portfolio Compare Chart

9.10

P/E

0.00

D/E

-93.6%

ROE

-79.2%

ROA

0.00%

Div Yield

-113.70

PEG

NEUPHORIA THERAPEUTICS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 4.49 Price -0.35 (-7.23%) Day Change	NEWS SCORE: 75

NEUP, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) そしてテクニカルスコアは ...(Sign In to See)...

Loading chart...

38 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROEが低い
ROAが低い
平均ROEが低い
ROEが昨年度比で低い
ROAがROEに比べて低い
昨年度のROAが一昨年比で低い
NPMの伸びが低い
NPMの伸びが低い

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Lorem ipsum dolor sit amet

Unlock timing signals and detailed reasons

In details, quality factors are not quite good , financial health is not quite good , and ability to make profit is ok , ...

Deepscope 分析

51%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	75
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	4.49
PBV / Sector	0.86 / 4.63 GREAT
Earning Per Share	-4.87

PE / Sector	9.10 / 17.43 GREAT
PEG or PE/Growth / Sector	-113.70 / 0.53
Average 1M Daily Value	0.30 M GREAT
Average 1W Daily Value	0.41 M GREAT

Timing Factors

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

50%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

ポイントになる統計

60%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	263.11 / 449.48 GREAT
NPM Average (%) / Sector	-2,664.31 / -1,506.49
NPM Change Average (%) / Sector	N/A / 4,940.99
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-79.16 / 30.58
ROA Average (%) / Sector	-75.65 / -347.17
ROA Change Average (%) / Sector	2,324.18 / 5,125.52 GOOD
ROE (%) / Sector	-93.64 / -3.58
ROE Average (%) / Sector	-100.55 / 40.65
ROE Change Average (%) / Sector	1,842.83 / 2,109.80
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

配当

Dividend (%) / Sector	N/A / 0.05
Dividend Average (%) / Sector	N/A / 16.49
Dividend Change Average (%) / Sector	N/A / 4.17

登録情報

Analyze Date	2026-06-06 09:09:04
Symbol	NEUP
Name	NEUPHORIA THERAPEUTICS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	5.40 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	25.40 / 8,857.28

ニュース

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 100 Summit Drive, Burlington, MA, United States, 01803

Phone: 781 439 5551

Website: https://www.neuphoriatx.com

Sector: Healthcare >> Biotechnology

Description: Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105 for the treatment of cancer. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; and Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders. The company has a collaboration with Merck & Co., Inc. to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Burlington, Massachusetts.